ReviewFrontiers in oncology2025
Dynamic FDG PET/CT imaging: quantitative assessment, advantages and application in the diagnosis of malignant solid tumors.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Functional Renal Assessment via Dynamic LAFOVJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Discriminating inflammation from malignancy with short-dynamic patlak parametric 18 F-FDG PET/CT.European journal of nuclear medicine and molecular imaging · 2026Article
- Subtype-Specific Metabolic Patterns in Staging Breast Cancer: Insights from Conventional and Parametric PET Radiomics.Cancers · 2026Article
- Research progress and trends on PET/CT imaging of pancreatic cancer: a bibliometric analysis.Discover oncology · 2026Article
- Molecular Imaging of Pancreatic Duct Adenocarcinoma Using [Molecular imaging and biology · 2026Article
- Osteosclerotic changes on computed tomography as a prognostic biomarker in prostate cancer with bone metastases: insights and future directions.International journal of surgery (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dynamic imaging has obtained remarkable achievements among a variety of malignant tumors due to the development of multiple simplified scanning protocols and the emergence of whole-body PET/CT scanners, which promote wider application of dynamic PET/CT. In this paper, we mainly review the acquisition protocols of dynamic imaging, related kinetic parameters, advantages and the application of dynamic PET/CT imaging in malignant tumors, including lung cancer, hepatocellular carcinoma, breast cancer, pancreatic carcinoma, prostate neoplasm, and cancer of head and neck. Dynamic PET/CT imaging is increasingly being applied the diagnosis, staging, efficacy monitoring, and prognosis evaluation of malignant tumors. Although standardized uptake value is the most frequently employed semi-quantitative assessment index for static imaging, it is susceptible to several factors, thus cannot be used to evaluate the tracer kinetic information of the lesion. Dynamic PET/CT imaging can be used to achieve continuous assessment of the metabolic activity of a lesion over a certain time frame through quantitative measurement of kinetic parameters, such as the net uptake rate constant. Compared with conventional static imaging, dynamic scanning can be used for the early estimation of minute metabolic changes in tumors. Besides, dynamic scanning can directly and effectively reflect tracer uptake. Nevertheless, the intricacy of parameter analysis and the lengthy scanning time related to dynamic scanning limits its clinical application. Dynamic imaging has obtained remarkable achievements among a variety of malignant tumors due to the development of multiple simplified scanning protocols and the emergence of whole-body PET/CT scanners, which promote wider application of dynamic PET/CT. In this paper, we mainly review the acquisition protocols of dynamic imaging, related kinetic parameters, advantages and the application of dynamic PET/CT imaging in malignant tumors, including lung cancer, hepatocellular carcinoma, breast cancer, pancreatic carcinoma, prostate neoplasm, and cancer of head and neck.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.